Last reviewed · How we verify
NUSINERSEN SODIUM
NUSINERSEN SODIUM is a drug. It is currently FDA-approved (first approved 2016).
Nusinersen sodium is an oligonucleotide that acts as a positive modulator of SMN2 pre-mRNA. It is used to treat muscular atrophy, specifically spinal muscular atrophy, as indicated by clinical trials.
At a glance
| Generic name | NUSINERSEN SODIUM |
|---|---|
| Modality | Oligonucleotide |
| Phase | FDA-approved |
| First approval | 2016 |
Approved indications
Common side effects
Key clinical trials
- Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)
- Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NUSINERSEN SODIUM CI brief — competitive landscape report
- NUSINERSEN SODIUM updates RSS · CI watch RSS
Frequently asked questions about NUSINERSEN SODIUM
What is NUSINERSEN SODIUM?
NUSINERSEN SODIUM is a Oligonucleotide drug.
When was NUSINERSEN SODIUM approved?
NUSINERSEN SODIUM was first approved on 2016.
What development phase is NUSINERSEN SODIUM in?
NUSINERSEN SODIUM is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing